Israeli biotech Kitov has proved its NT219 anti-cancer treatment triggers irreversible shutdown of tumor survival pathways in multiple cancers. In a separate announcement, US biotech Coeptis will distribute Consensi – Kitov’s dual osteoarthritis pain and hypertension treatment in the US.
Shutting down cancer resistance
This entry was posted in Israel's Medical Achievements. Bookmark the permalink.